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Research Article
Targeting endothelin receptor signalling overcomes
heterogeneity driven therapy failure
Michael P Smith1, Emily J Rowling1, Zsofia Miskolczi1, Jennifer Ferguson1, Loredana Spoerri2,
Nikolas K Haass2,3, Olivia Sloss1, Sophie McEntegart1, Imanol Arozarena1,4, Alex von Kriegsheim5,
Javier Rodriguez5, Holly Brunton1, Jivko Kmarashev6, Mitchell P Levesque6, Reinhard Dummer6,
Dennie T Frederick7, Miles C Andrews8, Zachary A Cooper8, Keith T Flaherty7, Jennifer A Wargo8 &
Claudia Wellbrock1,*
Abstract
Approaches to prolong responses to BRAF targeting drugs in mela-
noma patients are challenged by phenotype heterogeneity. Mela-
nomas of a “MITF-high” phenotype usually respond well to BRAF
inhibitor therapy, but these melanomas also contain subpopula-
tions of the de novo resistance “AXL-high” phenotype. > 50% of
melanomas progress with enriched “AXL-high” populations, and
because AXL is linked to de-differentiation and invasiveness avoid-
ing an “AXL-high relapse” is desirable. We discovered that pheno-
type heterogeneity is supported during the response phase of BRAF
inhibitor therapy due to MITF-induced expression of endothelin 1
(EDN1). EDN1 expression is enhanced in tumours of patients on
treatment and confers drug resistance through ERK re-activation
in a paracrine manner. Most importantly, EDN1 not only supports
MITF-high populations through the endothelin receptor B (EDNRB),
but also AXL-high populations through EDNRA, making it a master
regulator of phenotype heterogeneity. Endothelin receptor antago-
nists suppress AXL-high-expressing cells and sensitize to BRAF inhi-
bition, suggesting that targeting EDN1 signalling could improve
BRAF inhibitor responses without selecting for AXL-high cells.
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Introduction
The MAP-kinase (MAPK) pathway is deregulated in the majority of
malignant melanomas, and targeting the primary driver of hyper-
active MAPK signalling, BRAF shows impressive initial responses in
patients. However, prolonged responses are challenged by the
development of resistance, often through mechanisms that allow
bypassing BRAF inhibition (Lito et al, 2013; Carlino et al, 2015).
These mechanisms can in principle be overcome by combining
BRAF with MEK inhibitors, and indeed, BRAF/MEK combination
therapies show significant improvement in progression-free survival
compared to BRAF inhibitor monotherapy (Flaherty et al, 2012;
Larkin et al, 2014; Long et al, 2016). However, some melanomas,
despite harbouring a mutant BRAF gene, express higher levels of
additional oncogenic drivers that confer intrinsic MAPK inhibitor
resistance. These melanomas are characterized by gene signatures,
which correlate with enhanced expression of the receptor tyrosine
kinase AXL (Sensi et al, 2011; O’Connell et al, 2013; Konieczkowski
et al, 2014; Muller et al, 2014; Tirosh et al, 2016). Nevertheless,
with objective response rates of 60–70%, the majority of patients
with BRAF mutant melanoma respond to MAPK inhibitors, and if
we are to improve progression-free survival in these patients, it is of
paramount importance to understand the biology of the responding
tumours before and on treatment.
Melanomas that regress with MAPK pathway inhibitors are char-
acterized by the expression of the lineage-specific transcription
factor MITF (Konieczkowski et al, 2014; Wellbrock & Arozarena,
2015). MITF is detected in ~70% of treatment naive melanomas,
which have been classified as MITF-high (Sensi et al, 2011; Tirosh
et al, 2016). However, the situation is more complex; while
weak MITF-expressing cells are sensitive to MAPK inhibitors,
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up-expression of MITF provides resistance (Haq et al, 2013; Smith
et al, 2013, 2016; Muller et al, 2014). This is reflected in the fact
that some patients relapse with up-regulated MITF expression,
partly due to gene amplification (Muller et al, 2014; Van Allen et al,
2014; Smith et al, 2016).
As mentioned above, at bulk-tumour level, melanomas can be
classified as either MITF-high or AXL-high, but single-cell sequenc-
ing has revealed intra-tumour heterogeneity, whereby MITF-high
melanomas also contain cells with elevated AXL expression (Tirosh
et al, 2016). Importantly, this heterogeneity can have profound
consequences for therapy response; when patients eventually
acquire resistance to MAPK inhibitors, > 50% of resistant tumours
show enrichment for AXL-high populations (Tirosh et al, 2016). As
high AXL expression is linked to a more invasive phenotype (Sensi
et al, 2011; Muller et al, 2014), acquiring resistance with this pheno-
type could lead to a more aggressive state, which could be further
supported by the regressing tumour microenvironment (Obenauf
et al, 2015). Thus, avoiding a relapse with AXL-high tumours would
be desirable for the implementation of salvage therapies. With this in
mind, and to improve our understanding of the complexity of MITF-
high melanomas in the context of MAPK inhibitor resistance, we set
out to analyse the dynamics of individual MITF-expressing subpopu-
lations during treatment with BRAF inhibitor.
Results
Heterogeneous MITF expression is maintained during BRAF
inhibitor treatment
We have shown recently that in ~80% of patients on treatment with
MAPK inhibitors bulk-tumour MITF mRNA increases due to tran-
scriptional up-regulation (Smith et al, 2016). Furthermore, we
revealed that MITF up-expression enhances MAPK inhibitor resis-
tance during the drug-induced tolerance phase preceding acquired
resistance (Smith et al, 2016).
To assess the consequences of MITF up-expression within a
tumour at the single-cell level, we analysed a “MITF-high” melanoma
sample from a patient, who showed a response on vemurafenib treat-
ment (BRAFi, Appendix Table S1 for patient information). We found
that before treatment basal MITF expression was heterogeneous with
pools of weak, strong or undetectable MITF-expressing cell popula-
tions (Fig 1A). This was seen also in other melanoma biopsies
(Fig EV1A) and is entirely in line with single-cell analysis data from
MITF-high melanomas (Tirosh et al, 2016). Confirming our previous
findings, 2 weeks into treatment, bulk-tumour MITF expression was
increased in the tumour of patient 24 (Fig 1A). However, at the indi-
vidual cell level, the MITF expression pattern was still heterogeneous.
A similar heterogeneity was seen in other tumour samples from
patients on treatment, even when the overall expression level of
MITF did not increase (Appendix Fig S1). This suggested that despite
MITF’s function in drug resistance, no stringent selection for cells
with increased MITF expression levels had occurred on treatment.
Nevertheless, the heterogeneity could be due to the presence of popu-
lations of cells that differ in their genetic background, enabling them
to resist the drug insult independently of MITF.
To address this issue, we analysed melanoma xenografts derived
from the MITF-expressing cell line A375 (MITF-high), and as such a
population of genetically identical cells. Again we found that while
MITF was up-regulated in BRAF inhibitor-responding tumours, its
expression was heterogeneous throughout, and strong and weak
MITF-expressing cells were detectable (Fig EV1B). Possibly, in this
in vivo situation stroma-derived signals from the local tumour
microenvironment could have differing effects on MITF expression
(Smith et al, 2014). We therefore isolated cells from A375 xeno-
grafts that responded to and regressed on BRAF inhibitor. The over-
all increase in MITF expression was still detectable in these ex vivo
cultures in the absence of a microenvironment, but intriguingly
MITF heterogeneity prevailed, and stronger and weaker MITF-
expressing cells were detected (Fig 1B). Importantly, the presence
of weaker MITF-expressing cells was not due to enrichment for a
“AXL-high/MITF-low” population—considered the most resistant
phenotype—as this fraction was rather reduced in cultures respond-
ing to BRAF inhibitor (Fig EV1C and D).
We therefore attempted to monitor the dynamics of individual
cells within one MITF-high cell line in the response to MAPK inhibi-
tion in more detail. To identify a representative cell line, we
assessed the AXL and MITF expression status in a panel of mela-
noma cell lines and their link to response to BRAF inhibition. In
agreement with previous reports, we found a correlation with high
AXL expression and low MITF expression and resistance to BRAF
inhibition (Fig 1C). The group of MITF-expressing cell lines
displayed a considerable distribution of MITF expression levels, and
whereas weaker expression correlated with BRAF inhibitor sensitiv-
ity, increased MITF expression protected from BRAF inhibition
(Fig 1C).
We chose WM164 cells as they express intermediate MITF and
AXL levels and respond to BRAF inhibition (Fig 1C). In untreated
WM164 cells, MITF expression is heterogeneous (Fig 1D), which
allowed us to assess whether high MITF expression will be selected
for over the time of treatment. Using the FUCCI system, which can
report on the individual phases of the cell cycle, we followed single
FUCCI-WM164 cells (Haass et al, 2014) over the course of treatment
for 3 days, a time suitable for real-time imaging and during which
we already observe MITF up-expression in response to BRAF inhi-
bitor (Fig 1D). In a DMSO, control population cells cycle in a fairly
asynchronous mode with up to three cell divisions over 72 h
(Fig 1E). Treatment with BRAF inhibitor led to a G1 arrest within
12 h in the majority of cells. Within 24–48 h after the G1 arrest,
~20% of cells died (detectable by DRAQ7 staining) and another
10% started dying during the remaining time of the experiment
(Fig 1E). Occasionally, we observed that after exiting mitosis one
daughter cell died, while the other daughter cell stayed arrested in
G1 (Fig 1E, dashed line), suggesting great complexity in inhibitor
response even within one cell line. While overall the behaviour of
WM164 cells is in line with selection for more drug-resistant cells
arrested in G1, this was not reflected at the single-cell MITF
expression level, where heterogeneity was maintained (Fig 1D).
Again, there was no enrichment for AXL-high/MITF-low cells in
BRAF inhibitor-responding WM164 cells (Fig EV1E and F).
BRAF inhibitor pre-treated cells support the growth and survival
of BRAF inhibitor sensitive cells in vivo
The fact that MITF heterogeneity was still maintained during the
course of treatment in various experimental settings suggested
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that cells with basal MITF expression levels could withstand the
drug insult in the presence of cells with up-expressed MITF levels.
To test this, we “created” heterogeneous xenografts containing
A375-T cells alongside A375 cells. A375-T cells display treatment-
induced up-expression of MITF (Fig 2A), and as a consequence,
A375-T cells are more resistant to BRAF inhibition (Fig 2B and
Smith et al, 2016). We injected GFP-expressing A375 cells
together with RFP-expressing A375-T cells into zebrafish embryos
as described (Chapman et al, 2014), and monitored xenograft
growth. As expected, A375-T xenografts were more resistant to
A
C
E
B
D
Figure 1.
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BRAF inhibition and still grew in the presence of drug (Fig 2B
and C). Moreover, in heterogeneous xenografts A375-T cells could
protect A375 cells from BRAF inhibitor-induced growth inhibition
(Fig 2C and D), thereby maintaining heterogeneity. In addition,
even in the absence of drug, the presence of A375-T cells in
heterogeneous xenografts appeared to have a growth stimulating
effect on A375 cells (Fig 2D). This was also seen in melanoma
spheres grown in 3D dermal collagen, where A375-T had a pro-
proliferative effect on A375 cells (Fig EV2).
Paracrine protection is a general concept
To test whether the above observed co-culture protection was medi-
ated by soluble factors being produced in response to drug treat-
ment, we exposed A375 cells to BRAF inhibitor over the course of
14 days, and periodically collected conditioned medium at 3, 7 and
14 days. Exposing parental sensitive cells to these conditioned
media reduced the efficacy of BRAF inhibition, and these effects
were most significant after 7–14 days (Fig 3A). A similar effect was
observed with conditioned medium from three other BRAFV600E
melanoma cell lines WM164, M249 and WM9 (Figs 3A and EV3A).
Although differing in their time course, after 14 days all cell lines
displayed enhanced MITF expression and were significantly more
tolerant to BRAF inhibitor than their respective parental cell lines
(Fig 3A and Appendix Fig S2). The transient nature of this drug-
induced secretome was seen when cells were taken off the drug,
which resulted in the reduction of MITF expression and loss of the
protective effect brought about by the conditioned medium
(Fig EV3B and C).
To create a situation in which both cell populations are exposed
to drug at the same time, but soluble factors can be effective, we co-
cultured sensitive parental cells with their tolerant daughter cells
separated by a permeable membrane (Fig 3B). In this setting, we
could confirm that soluble factors were activating a protective
signalling. Moreover, we found that pre-treated melanoma cells
could produce this effect in other melanoma cell lines and that
innate-resistant high MITF-expressing cell lines (Smith et al, 2013)
can also produce such a paracrine protective effect (Fig 3C).
Thus, prolonged BRAF inhibition leads to the production of a
secretome that counteracts the growth suppressive effects of MAPK
pathway inhibition. While this secretome possibly acts in an auto-
crine fashion, we show here that it also can act in a paracrine mode,
thereby protecting otherwise drug-sensitive cells.
Paracrine protection involves re-activation of the MAPK pathway
via PKC
To further dissect the mechanism of paracrine protection, we
assessed MAPK pathway activation and found that the co-culture
with 14 days pre-treated cells led to a partial rescue of ERK phos-
phorylation in sensitive cells in the presence of a BRAF inhibitor
(Fig 3D). A similar effect was observed with A375 ex vivo cultures
isolated from tumours that had regressed on BRAF inhibitor
(Fig EV3D), as well as with in vitro generated A375-T cells
(Fig EV3E). MEK inhibition could overcome the paracrine protection
and ERK re-activation mediated by soluble factors (Fig EV3E). This
indicated that ERK re-activation occurs upstream of MEK, and the
most prominent candidate for this activation is CRAF. We thus used
the pan-RAF inhibitor RAF265, which abolished the re-activation of
ERK phosphorylation (Fig 3E) and completely overcame the protec-
tive effect produced by A375-T cells (Fig 3F). A similar effect was
observed in other melanoma cell lines when they were treated with
conditioned medium (Fig EV3F). Using specific inhibitors to identify
the upstream activator of CRAF revealed that the pan-PKC inhibitor
GO-6983 (PKCi) was able to overcome ERK re-activation and the
protective effect produced by co-culturing A375 cells with A375-T
cells (Fig 3E and F). These data strongly suggest that prolonged
BRAF inhibition triggers the production of secreted factors capable
of re-activating the pathway via PKC and CRAF. Indeed, treatment
of melanoma cell lines with conditioned medium derived from
corresponding cell lines treated for 14 days with BRAF inhibitor,
resulted in an increase in the phosphorylation of proteins recog-
nized as PKC substrates (Fig 3G).
The secretome of BRAF inhibitor pre-treated cells is enriched
in Endothelin-1
A quantitative proteomics analysis of conditioned medium from
untreated A375 and A375-T cells (applying a cut-off of twofold
change) identified 387 proteins that were enriched in the condi-
tioned medium of pre-treated A375-T cells; amongst these were 77
secreted/extracellular space-signalling proteins (Fig 4A). Ingenuity
Pathway Analysis identified 27 of these 77 proteins as activators of
ERK (Fig 4B). Amongst these was EGF, which together with its
receptor has been previously implicated in BRAF inhibitor resistance
through reactivation of ERK (Girotti et al, 2013; Sun et al, 2014).
Nevertheless, while EGFR expression was up-regulated in A375-T
◀ Figure 1. MITF heterogeneity is maintained during MAPK inhibitor treatment.A Immunofluorescence analysis for MITF (magenta) in a tumour of a patient, who had been treated with dabrafenib for 2 weeks. Nuclei were stained with DAPI. Scale
bar: 10 lm. Relative MITF mRNA expression assessed by qRT–PCR is shown. P: probability by paired t-test: *P = 0.0219. Error bars: SD of three replicate measures.
B A375-GFP cells were isolated from xenografts grown in mice (n = 6) that had been treated with vehicle or 100 mg/kg vemurafenib (BRAFi) for 12 days (maximum
response). The tumour volume is indicated (mean  SD; horizontal black line, 100 mm3, volume at start); P: probability by t-test: ***P = 0.001. The ex vivo cultures
were analysed for MITF expression by Western blot and immunofluorescence (magenta). Nuclei were stained with DAPI. Scale bar: 20 lm (white arrows, high MITF;
black arrows, low MITF).
C Relative AXL and MITF expression in a panel of melanoma cell lines that have been characterized for their response to BRAF inhibition (Barretina et al, 2012; Garnett
et al, 2012; Smith et al, 2013).
D MITF immunofluorescence analysis of WM164 cells treated with DMSO or dabrafenib for 72 h. Scale bar: 10 lm. Relative MITF mRNA expression assessed by
qRT–PCR is shown (n = 3 independent experiments; mean  SEM). P: probability by paired t-test: **P = 0.0095 (white arrows, high MITF; black arrows, low MITF).
E Time-lapse analysis of mKO2-hCdt1 and mAG-hGem (FUCCI) expressing WM164 melanoma cells (Haass et al, 2014) over 72 h. Cells were either treated with DMSO or
dabrafenib. Dashed lines indicate cells whose daughter cells underwent different fates after exiting mitosis.
Source data are available online for this figure.
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cells, it was hardly detectable in A375 cells (Appendix Fig S3A),
which suggests that EGF can act in an autocrine fashion on A375-T
cells, but it is unlikely to contribute to the paracrine effects observed
in A375 cells.
In an attempt to narrow down the list of potential ERK re-activa-
tors, we applied a predictive algorithm for the isolation of upstream
regulators of the proteins enriched in the conditioned medium. This
analysis identified the MiT family factors TFEB and MITF amongst
the transcriptional regulators with the highest significance (Fig 4C).
Indeed, MITF depletion abolished the ability of A375-T cells to
enhance A375 cell survival in the presence of BRAF inhibitor
(Fig 4D). This indicated that in A375-T cells, MITF contributes to
paracrine protection by regulating the abundance of relevant
secreted proteins.
We therefore analysed the 27 potential ERK activators for puta-
tive MITF targets (Hoek et al, 2008; Strub et al, 2011). While
several MITF regulated factors (Fig 4B, labelled red) can contri-
bute to activation of ERK in a CRAF-dependent manner, there
was no obvious link to PKC activation. We therefore extended the
list of MITF targets to regulators of secreted factors. This led to
the identification of endothelin-converting enzyme-1 (ECE-1,
Fig 4B), whose expression in A375-T cells was indeed dependent
A
C
D
B
Figure 2. MITF heterogeneity counteracts MAPK inhibitor-induced growth inhibition in vivo.
A Western blot of A375 or A375-T cells depicting basal expression of MITF. ERK2 served as loading control.
B A375 or A375-T cells were treated with vemurafenib (BRAFi) for 72 h before relative cell number was assessed. A Western blot for MITF in A375 and A375-T cells is
shown. P: probability by one-way ANOVA (with Tukey’s post hoc test); ***P < 0.0001 (A375) and **P = 0.0022 (A375-T).
C GFP-expressing A375 or RFP-expressing A375-T cells were injected into the pericardial space of zebrafish embryos, before they were treated with either vemurafenib
(BRAFi) or DMSO. The total number of cells for each injection condition was 1,000 cells. Xenografts were imaged at day 1 and day 4 of drug treatment using a Leica
SP5 confocal microscope, and fold change in volume of populations of GFP- or RFP-expressing cells at day 4 compared to day 1 is indicated. Scale bar: 100 lm.
D Xenograft volumes seen in 3D images at day 1 and day 4 of treatment were quantified using Volocity® software. Fold change relative to day 1 is shown. P: probability
by one-way ANOVA (with Tukey’s post hoc test); ***P < 0.0001.
Data information: Data are pooled of n = 3 independent experiments and are shown as mean  SEM.
Source data are available online for this figure.
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on MITF (Fig 4E) and was up-regulated in MAPK inhibitor-treated
cells (Appendix Fig S3B). What made ECE1 such an attractive
regulator is that it produces biologically active endothelin-1
(EDN1), a crucial factor for the development of the melanocytic
lineage (Imokawa et al, 2000; Saldana-Caboverde & Kos, 2010)
that activates MAPK signalling through EDNRB in a PKC/CRAF-
dependent manner (see Fig 4B). Indeed, when we analysed the
conditioned medium of A375-T cells using a specific ELISA, we
could detect considerable levels of EDN1, which were profoundly
reduced when ECE1 activity was inhibited (Fig 4F). Thus, EDN1
is produced by A375-T cells and the most likely reason for not
being able to detect EDN1 in the mass spectrometry analysis
could be the molecular weight cut-off (3–5 kD) we had chosen,
as the mature EDN1 peptide consists of only 21 aa. Nevertheless,
an involvement of EDN1 in drug-induced paracrine tolerance was
further supported by the fact that its levels were also increased in
the medium of all cell lines that had been treated with BRAF inhi-
bitor for 14 days (Fig 4G).
Endothelin-1 antagonizes BRAF inhibition via PKC activation
While the increase in EDN1 protein in the conditioned medium
could be solely due to the enhanced processing by ECE1, we
wondered whether EDN1 expression itself was also up-regulated in
response to long-term treatment with MAPK inhibitors. Indeed, the
analysis of two A375-T cell cultures for EDN1 protein revealed
enhanced expression compared to A375 cells (Fig 5A). This increase
was also seen at mRNA level in A375-T cultures as well as in a
whole range of BRAF inhibitor-treated melanoma cells including
ex vivo cultures (Appendix Fig S4A–C). Moreover, MITF depletion in
A375-T cells resulted in a significant reduction in EDN1 mRNA and
protein expression (Fig 5B), and overexpression of MITF resulted in
increased EDN1 expression (Appendix Fig S4D). This indicated that
MITF is not only involved in the production of the mature peptide
via ECE1, but also in the regulation of EDN1 expression.
Exposure of A375 cells to recombinant active EDN1 led to ERK
activation in a dose-dependent manner (Appendix Fig S4E). As
◀ Figure 3. Paracrine protection is a general trait of drug-tolerant melanoma cells and dependent on RAF and PKC.A Dose–response curves for vemurafenib (BRAFi) in the indicated cell lines. The respective cell lines were treated with either DMEM (control) or conditioned medium,
which was derived from the respective cell line treated with vemurafenib for the indicated times. Western blots for MITF with ERK2 as loading control are shown.
B Schematic of co-culture assay of drug-tolerant and drug-sensitive melanoma cells. Drug-sensitive cells were co-cultured with either drug-sensitive cells or cells that
had been pre-treated with vemurafenib for 14 days. The co-cultures were treated for 48 h with vemurafenib (BRAFi) before quantitative analysis of paracrine
protection. Paracrine protection was determined as difference between co-culture with sensitive cells and drug pre-treated cells. P: probability by one-way ANOVA
(with Tukey’s post hoc test); **P = 0.0022 (A375), *P = 0.0307 (M249), **P = 0.0084 (WM9) and ***P < 0.0001 (WM164).
C Analysis of paracrine protection in a panel of drug-tolerant and drug-sensitive melanoma cells. Drug-sensitive A375, WM9 or WM98 cells were co-cultured with the
indicated melanoma cell cultures, and paracrine protection was determined as indicated in (B).
D Western blot of the indicated cell cultures for pERK and total ERK. The indicated cultures were co-cultured with either untreated cells (control) or with the respective
drug pre-treated cell lines. Cells were treated with DMSO or with vemurafenib (BRAFi) for 24 h.
E Western blot of the indicated cell cultures for pERK and total ERK. Cells were either treated with DMSO or treated with vemurafenib (BRAFi) in the presence or
absence of RAF265 or GO-6983 (PKCi).
F Quantification of relative cell numbers. A375 cells were co-cultured with either A375 or with A375-T cells. DMSO-treated A375 cells in the presence of A375 cells were
set at 100%. P: probability by t-test: ns P > 0.05, ***P < 0.0001 and *P = 0.0312.
G Western blot for pERK and proteins that represent PKC substrates. ERK served as loading control. The indicated cell lines had been either left untreated or were
treated with conditioned medium derived from the respective drug pre-treated (14 days) cell lines.
Data information: Data are pooled of n = 3 independent experiments and are shown as mean  SEM.
Source data are available online for this figure.
▸Figure 4. MITF produces paracrine protection through a secretome containing EDN1.A Schematic presentation of groups of proteins detected by quantitative mass spectrometry to be enriched in conditioned medium of A375-T cells when compared to
A375 cells.
B Ingenuity Pathway Analysis of factors in the extracellular space for involvement in the activation of ERK. MITF targets are indicated in red font.
C Ingenuity Upstream Regulator Analysis shows the potential transcriptional regulators that can explain changes observed in secreted proteins. Proteins that were
up-regulated in the media of drug-treated cells (FC > 2, FDR < 0.05) were selected for IPA analysis, and upstream transcriptional driver were identified. The Z-score
indicates activation states of predicted regulators with positive values corresponding to activated transcription regulator activating gene expression.
D Quantification of relative cell number and analysis of ERK phosphorylation of A375 cells when co-cultured with either A375 or with A375-T cells. DMSO-treated A375
cells in the presence of A375 cells = 100%. Before co-culture, A375-T cells were treated with a control or two different MITF-specific siRNAs (siMI1, siMI3). A Western
blot demonstrating the degree of MITF knockdown is shown. ERK served as loading control. P: probability by one-way ANOVA (with Tukey’s post hoc test); ns P > 0.05,
**P = 0.0047 (A375 co-culture vs. A375-T co-culture).
E qRT–PCR for ECE1 expression in the indicated melanoma cell lines treated with a control (sicon) or two different MITF-specific siRNAs (siMI1, siMI3). A Western blot
demonstrating the degree of MITF knockdown is shown. ERK served as loading control. P: probability by one-way ANOVA (with Tukey’s post hoc test); ***P < 0.0001
(A375-T siMi1 and siMi3, A375-T2 siMi1), ***P = 0.0003 (A375T2-siMI3).
F A375-T cells were left untreated or treated for 24 h with 15 lM ECE1 inhibitor CGS 35066 before EDN1 levels in the medium were analysed by ELISA. P: probability by
t-test: ***P < 0.0001.
G ELISA measuring EDN1 concentrations in the medium of the indicated cell lines. Cells were either untreated or had been treated with BRAFi for 14 days. P: probability
by one-way ANOVA (with Sidak’s post hoc test); ***P < 0.0001 (WM9, M249), **P = 0.0013 (WM98) and *P = 0.0238 (A375).
Data information: Data are pooled of n = 3 independent experiments and are shown as mean  SEM.
Source data are available online for this figure.
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expected, EDN1 increased the phosphorylation of PKC substrates in
addition to ERK, which was however completely abolished in the
presence of a PKC inhibitor (Fig 5C). The EDN1-mediated ERK acti-
vation was more obvious in the presence of a BRAF inhibitor, where
it could maintain phospho-ERK levels in a RAF-dependent manner
(Fig 5C). Accordingly, EDN1 protected against inhibitor-induced
growth inhibition, and in line with a role for PKC, RAF and MEK,
this protection was reduced in the presence of respective inhibitors
(Figs 5D and EV4A). Furthermore, RNAi-mediated EDN1 depletion
from A375-T cells used in transwell co-culture assays significantly
reduced paracrine protection (Fig EV4B), and similar effects were
seen with an EDN1 neutralizing antibody (Fig EV4C).
EDNRB is required for paracrine protection
EDN1 signals through endothelin receptors, of which EDNRB is
essential for melanocyte development (Saldana-Caboverde & Kos,
2010), and its expression is highly enriched in melanoma cells
(Fig EV4D). Indeed, EDNRB depletion through RNAi prevented
EDN1 from protecting melanoma cells from BRAF inhibition
(Fig 5E). To assess the relevance of EDNRB for paracrine protection
in vivo, we co-injected A375-T cells with A375 control cells or with
A375-shEDNRB cells into zebrafish embryos, and monitored cell
death within tumours in the absence or presence of BRAF inhibitor.
As seen for A375 cells, BRAF inhibition reduced the volume of
A375-shEDNRB xenografts (Fig 5F). However, in contrast to what
we observed in A375 cells, A375-T cells were not able to protect
A375-shEDNRB cells from BRAF inhibition (Fig 5F), indicating that
EDNRB-mediated signalling plays an important role in paracrine
protection to MAPK pathway inhibition in melanoma cells.
To assess the pharmacological intervention of this signalling, we
used EDN receptor (EDNR) antagonists bosentan and macitentan,
which are currently used to treat pulmonary artery hypertension,
but are also being trialled in solid cancers (Rosano et al, 2013). Both
drugs could overcome the paracrine protection brought about by
A375-T cells (Fig 5G). Bosentan also partially restored the sensitiv-
ity of a panel of parental cell lines to BRAF inhibition when they
were “protected” by conditioned medium from pre-treated cells
(Fig EV4E). Finally, macitentan overcame paracrine protection and
ERK re-activation induced by conditioned medium from A375 cells
ectopically overexpressing MITF (Appendix Fig S4F and G), further
supporting the link between MITF, EDNR signalling and paracrine
protection.
Targeting EDNR enhances BRAF inhibitor efficacy in vivo and
suppresses enrichment for AXL-high cell populations
Our data suggest that blocking EDNRB-mediated signalling could
improve BRAF inhibitor responses by preventing EDN1-mediated
paracrine signalling. In order to test whether therapeutic interven-
tion with EDNRB signalling represents a relevant strategy for mela-
noma patients, we analysed melanoma samples isolated from
patients when they had been on treatment for 2 weeks. In line with
our previous findings that MITF is up-regulated on treatment (Smith
et al, 2016), we found that EDN1 as well as EDNRB expression
increased in melanomas of patients (n = 22) on treatment (Fig 6A).
Moreover, EDN1 is up-regulated in short-term cultures from mela-
nomas from patients on treatment (see Appendix Table S2 for
patient details), and these cultures also provide paracrine protection
(Fig EV4F and G), supporting the relevance of our findings in
patients.
To assess the efficacy of targeting EDNRB signalling, we treated
mice bearing A375 tumours either with BRAF inhibitor alone or a
BRAF inhibitor/bosentan combination and found that growth was
significantly reduced with the combination treatment (Fig 6B).
Under the chosen conditions, ERK phosphorylation and activity
(assessed through the surrogate marker DUSP6) was reduced with
BRAF inhibitor (Fig 6C), but the combination treatment led to a
significant further reduction, supporting the idea that EDNRB signal-
ling contributes to ERK activation within these tumours. The
reduced ERK activity in BRAF inhibitor-treated tumours correlated
with increased MITF and EDN1 expression (Fig 6D). However, both
EDN1 and MITF up-regulation was further enhanced with the BRAF
inhibitor/bosentan combination treatment (Fig 6D). While this is in
line with the observed strong reduction in ERK activation, it demon-
strates that, although EDN1 is up-regulated, antagonizing EDNR
signalling can severely block tumour growth.
Because on BRAF inhibitor monotherapy tumour growth had
resumed despite ERK being still inhibited, we wanted to see whether
these MITF-high tumours are enriched for AXL-high cell popula-
tions. Indeed, AXL expression was increased in tumours growing on
BRAF inhibitor monotherapy (Fig 6E). Intriguingly however,
▸Figure 5. MITF produces paracrine protection through EDN1-mediated PKC activation.A Western blot for EDN1 and MITF expression in A375, A375-T and A375-T2 cells. Beta-tubulin and ERK2 served as loading control, respectively.
B qRT–PCR for EDN1 expression and Western blot for EDN1 in A375-T cells after treatment with either a control siRNA (sicon) or two different MITF-specific siRNAs
(siMI1, SiMI3). P: probability by one-way ANOVA (with Tukey’s post hoc test); ***P < 0.0001.
C A375 cells were stimulated with EDN1 for 8 h and analysed for phosphorylation of PKC substrates, pERK and total ERK on a Western blot. Cells were treated with
DMSO or GO-6983 (PKCi) before analysis (upper panel), or vemurafenib (BRAFi, middle panel) or RAF265 (lower panel).
D Quantification of relative cell number of A375 cells when treated with EDN1 in the absence or presence of vemurafenib (BRAFi) and GO-6983 (PKCi) or RAF265.
P: probability by one-way ANOVA (with Tukey’s post hoc test); ns P > 0.05, ***P = 0.0006.
E Quantification of relative cell number of A375-pLKO or A375-shEDNRB cells when treated with EDN1 in the absence or presence of BRAFi. P: probability by one-way
ANOVA (with Tukey’s post hoc test); ns P > 0.05, ***P = 0.0003.
F GFP-A375 pLKO, GFP-A375 shEDNRB or RFP-A375-T cells were injected into the pericardial space of zebrafish embryos, and the embryos were treated with either
vemurafenib (BRAFi) or the vehicle DMSO. Images at day 1 and day 4 of treatment are shown, and fold change in volume at day 4 compared to day 1 was quantified.
Scale bar: 100 lm. P: probability by one-way ANOVA (with Tukey’s post hoc test); ns P > 0.05, *P = 0.026 (DMSO), ***P < 0.0001 (BRAFi).
G Quantification of relative cell number of A375 cells when co-cultured with either A375 or with A375-T cells in the absence or presence of BRAFi, alone or in
combination with bosentan or macitentan. P: probability by one-way ANOVA (with Tukey’s post hoc test); ***P < 0.0001 (all).
Data information: Data are pooled of n = 3 independent experiments and are shown as mean  SEM.
Source data are available online for this figure.
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Figure 6. Inhibition of EDNR signalling in vivo reduces tumour growth and counteracts AXL up-regulation.
A Analysis of EDN1 and EDNRB expression in patients. Immunofluorescence analysis for MITF and EDN1 expression in the tumour of patient 24 before and on
treatment. Scale bar: 10 lm. EDN1 and EDNRB qRT–PCR analysis in tumours of patients on treatment with either vemurafenib alone or a dabrafenib/trametinib
combination (n = 22). P: probability by t-test; **P = 0.0064 (EDN1) and **P = 0.0033 (EDNRB).
B Nude mice bearing A375 tumours were treated (n = 5–6 mice per group) with vehicle, vemurafenib (25 mg/kg/qd) or bosentan (25 mg/kg/qd) alone or in
combination for 20 days. Data are presented as mean tumour volumes  SEM.
C Phospho-ERK IHC and qRT–PCR for DUSP6 from tumours corresponding to the experiment described in (B). Scale bar: 200 lm. P: probability by one-way ANOVA
(with Tukey’s post hoc test); ns P > 0.05, *P = 0.0186 (BRAFi) and ***P = 0.0004 (combo).
D qRT–PCR for MITF and EDN1 from tumours corresponding to the experiment described in (B). P: probability by one-way ANOVA (with Tukey’s post hoc test);
ns P > 0.05, *P = 0.0179 (MITF-BRAFi), ***P < 0.0001 (MITF-combo), ***P < 0.0001 (EDN1-BRAFi) and ***P < 0.0001 (EDN1-combo).
E, F qRT–PCR for AXL, and EDNRA and EDNRB from tumours corresponding to the experiment described in (B). P: probability by one-way ANOVA (with Tukey’s post hoc
test); ns P > 0.05, *P = 0.0341 (EDNRA-Bosentan) and ***P < 0.0001 (AXL-BRAFi, EDNRA-BRAFi, EDNRB-BRAFi and EDNRB-combo).
G qRT–PCR for EDNRA and EDNRB in tumours of patients on treatment with either vemurafenib alone or a dabrafenib/trametinib combination. Relative basal
expression of EDNRA and EDNRB was considered. P: probability by t-test; *P = 0.0116 (EDNRA) and **P = 0.0039 (EDNRB).
Data information: Data are pooled of n = 3 independent experiments and are shown as mean  SEM. Box and whiskers plots with median (horizontal line), second and
third quartiles (box limits) and min and max values (error bars).
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addition of bosentan overcame this increase in AXL expression,
which suggested that blocking EDNR signalling also affects AXL-
high cells.
This was surprising as EDNRB expression is linked to the MITF-
high signature and not found in the AXL-high signature (Hoek et al,
2006). However, it has to be noted that EDN1 not only activates
EDNRB but is also a strong activator of EDNRA. We therefore
assessed EDNRA expression in the A375 xenografts and found that
although it was expressed at much lower levels than EDNRB, its
expression was up-regulated in BRAF inhibitor-treated tumours
(Fig 6F). A similar situation was observed in melanomas from
patients, where EDNRA expression levels were also lower than
EDNRB levels and were increased on treatment (Fig 6G). This
suggested that EDNRA could also contribute to EDN1 signalling in
patients during therapy. Intriguingly, in xenografts, the BRAF inhi-
bitor/bosentan combination treatment led to a significant suppres-
sion of EDNRA expression within the residual tumours (Fig 6F),
which correlates with the drop in AXL expression (Fig 6E).
AXL-high cell populations require EDN1 to overcome
BRAF inhibition
As mentioned above EDNRB but not EDNRA expression is linked to
the MITF-high signature. Because we saw a correlation of AXL
expression with EDNRA expression in the xenografts, we interro-
gated publicly available gene expression data, including the TCGA-
melanoma as well as two melanoma cell line datasets (Barretina
et al, 2012; Garnett et al, 2012; TCGANetwork, 2015). We found
that in the TCGA dataset MITF was positively correlated with
EDNRB, but negatively correlated with EDNRA expression (Fig 7A).
On the other hand, EDNRA expression positively correlates with
AXL, and EDNRA and EDNRB expression are inversely correlated
(Figs 7A and EV5A and B). We could further confirm the mutual
exclusion of MITF/EDNRB and AXL/EDNRA expression in a panel
of melanoma cell lines (Fig 7B).
The specific expression of EDNRA in AXL-high cells and the
effect of the BRAF inhibitor/bosentan combination therapy on these
cells suggested that EDNRA signalling is relevant for the growth of
AXL-high cells. Nevertheless, in contrast to MITF-high cells, recom-
binant EDN1 alone did not increase basal proliferation of these cells
(not shown). However, in the presence of BRAF inhibitor, which
produced a significant reduction in cells in S-phase, EDN1 provided
a clear advantage and stimulated cell cycle progression (Fig 7C). A
similar protection was seen in AXL-high cells with EDN1-containing
conditioned medium from A375-T cells, whereby the EDNR antago-
nist bosentan overcame the protective effect of the medium
(Fig EV5C). It should be mentioned that while bosentan is a pan
EDNR antagonist, its affinity for EDNRA is ~20-fold higher than for
EDNRB (Clozel et al, 1994), explaining why it also affects AXL-high
cells. However, to further dissect the specific involvement of the dif-
ferent receptors in EDN1 signalling, we used inhibitors specifically
antagonizing EDNRA (BQ123) or EDNRB (BQ788). This revealed
that EDNRB was required in MITF-high cells and EDNRA was
required in AXL-high cells to transmit the paracrine protection
brought about by conditioned medium (CM) from A375-T cells
(Fig 7D and Appendix Fig S5). The paracrine effect was linked to
ERK phosphorylation, which was induced by the CM from A375-T
cells, whereby BQ788 overcame this activation in MITF-high A375
cells in BQ123 in AXL-high WM793 cells, respectively (Fig 7E).
In line with high AXL expression, WM793 cells were more
resistant to long-term BRAF inhibitor treatment when compared to
MITF-high A375 cells (Fig 7F). However, the inhibitor still reduced
the cell number over time (Fig 7F), which is entirely in line with
observations in other AXL-high cell lines such as 1205Lu, IGR39,
294T and A2058 (Tsai et al, 2008; Beaumont et al, 2016; Tirosh
et al, 2016). It appears that AXL-high cells are less responsive to
BRAF inhibition, because despite slowing down cell cycle progres-
sion and reduce ERK activity (see Fig 7C and E), BRAF inhibition
does not induce apoptosis in AXL-high cells (Fig 7G and H).
Nevertheless, similar to what is seen in MITF-high cells, conditioned
medium from BRAF inhibitor pre-treated melanoma cells profoundly
protects AXL-high cells from the growth inhibitory effect of BRAF
inhibition (Fig 7F). However, bosentan overcomes this paracrine
protection in AXL-high cells, resulting in significant reduction in cell
number and this is related to reduced ERK activity (Figs 7F
and EV5D). Again use of BQ123, BQ788 as well as a specific
◀ Figure 7. EDNR signalling is required for proliferation in AXL-high cells.A Correlation analysis for the expression of the indicated genes using the TCGA-melanoma dataset (TCGANetwork, 2015).
B Real-time qPCR of EDNRA and EDNRB in the indicated MITF-high and AXL-high cell lines.
C Analysis of cells in S-phase. The indicated cell lines were treated with vemurafenib and 20 ng/ml EDN1 either alone or in combination for 24 h, and 4 h before
analysis EdU was added to the cultures. P: probability by one-way ANOVA (with Tukey’s post hoc test); ***P < 0.0001 (WM266-4, WM164, WM793), **P = 0.009 (A375),
*P = 0.0445 (RPMI7951).
D Analysis of cells in S-phase. The indicated cell lines were treated with vemurafenib (BRAFi), BQ788 or BQ123 either alone or in combination and in the presence of
conditioned medium from A375-T cells for 24 h, and 4 h before analysis EdU was added to the cultures. The conditioned medium from A375 cells was used as control.
P: probability by t-test; ns P > 0.05, ***P = 0.0007 (A375, BRAFi/BQ788) and ***P = 0.0009 (WM793, BRAFi/BQ123).
E Western blot of A375 and WM793 cells in the absence or presence of conditioned medium from A375-T cells treated with DMSO or BRAF inhibitor for phospho-ERK
and PKC substrates as indicated. ERK2 served as loading control.
F Quantification of relative cell numbers. A375 or WM793 cells were either left untreated or were treated with 0.5 lM vemurafenib (BRAFi) and bosentan either alone
or in combination in the presence of conditioned medium from A375-T cells for one week. DMSO-treated A375 cells were set at 100%. P: probability by one-way
ANOVA (with Tukey’s post hoc test); ***P < 0.0001.
G Western blot for the indicated proteins of the indicated cell lines with DMSO, vemurafenib (BRAFi) or BRAFi in the presence of conditioned medium from A375-T cells.
H Analysis for apoptosis using an incucyte® caspase-3/7 apoptosis assay reagent. The indicated cell lines were treated with DMSO, vemurafenib (BRAFi) alone or with
BRAFi +/ macitentan (Mac) in the presence of conditioned medium from A375-T cells and apoptosis activity was measured over time; end-point values at 48 h are
shown. P: probability by one-way ANOVA (with Tukey’s post hoc test); ns P > 0.05, ***P < 0.0001.
Data information: Data are pooled of n = 3 independent experiments and are shown as mean  SEM.
Source data are available online for this figure.
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EDN1-blocking antibody confirmed the contribution of the individ-
ual EDNRs to paracrine protection (Fig EV5E–G).
In order to dissect how EDNRA signals to ERK and hence
regulates cell growth, we used different kinase inhibitors and found
that while a PKC inhibitor did not impact on the protective function
of EDN1, inhibiting RAF kinases with RAF265 or blocking RTK
activity using the pan RTK inhibitor dovitinib overcame this protec-
tion (Fig EV5H and I). This suggests a crosstalk between EDNRA
and RTK signalling as it has been described previously (Harada
et al, 2014; Harun-Or-Rashid et al, 2016; Moody et al, 2017), which
ultimately activates ERK through RAF.
Targeting EDNRA or EDNRB reduces AXL-high populations in vivo
To further assess the specific contribution of EDNRB and EDNRA
signalling to the response to BRAF inhibition in vivo, we treated
mice bearing A375 tumours either with BQ788, which has a 1,000-
fold higher affinity for EDNRB than EDNRA (Okada & Nishikibe,
2002) or with macitentan with an approximately 800-fold higher
affinity for EDNRA than EDNRB (Boss et al, 2016). The EDNR inhi-
bitors were applied either alone or in combination with BRAF inhi-
bitor (Figs 8A and EV6A). After 20 days, tumours treated with
BRAF inhibitor alone had resumed growth, whereas ERK activity
was still moderately inhibited as seen by the reduced expression of
DUSP6 (Fig 8B). The combination of BQ788 with BRAF inhibitor led
to a significant reduction in tumour growth, which correlated with
strong suppression of DUSP6 expression (Fig 8A–C). The effect of
macitentan in the combination with BRAF inhibitor was weaker, but
it still led to a significantly stronger reduction in tumour growth
compared to BRAF inhibitor monotherapy (Figs 8C and EV6A).
Overall, when compared to BRAF inhibitor alone, the combination
with each of the three EDNR inhibitors bosentan, macitentan and
BQ788 reduced proliferation, measured through Ki67 staining
(Figs 8D and EV6B), and increased cell death, assessed by cleaved
caspase-3 staining (Figs 8E and EV6C).
The addition of macitentan to the BRAF inhibitor reduced the
expression of EDNRA within the tumours (Fig 8F), suggesting that
through its affinity for EDNRA macitentan targets the AXL/EDNRA-
expressing cells. Addition of BQ788 only slightly reduced EDNRA
expression, which was still elevated (Fig 8F). This observation
would be in line with the specific activity of BQ788 towards EDNRB-
expressing but not towards EDNRA-expressing cells. Similar to what
we observed with bosentan, BRAF inhibitor/BQ788-treated tumours
displayed increased expression of MITF and EDNRB (Fig 8G and H).
This response might be due to the fact that ERK is effectively inhib-
ited (Fig 8B), leading to MITF up-expression and eventually EDNRB
up-regulation. Under these conditions, EDN1 expression was still
significantly increased relative to vehicle control, but nevertheless
reduced when compared to BRAF inhibition alone (Fig 8I). This was
intriguing as it suggested that BQ788, despite enabling MITF up-
expression in the presence of BRAF inhibitor, had suppressed EDN1
expression within the tumours. One possible explanation is that
BQ788 affects other potential EDN1 sources. Indeed, inhibiting
EDNRB profoundly reduced the presence of endothelial cells
(Fig EV6D and E) and fibroblasts (Fig EV6F and G), both of which
were increased in response to BRAF inhibition (Fig EV6D and F).
If the paracrine action of EDN1 is crucial in vivo, reducing its
expression should have an effect on AXL/EDNRA-expressing cells,
even if BQ788 does not directly target EDNRA activity. We therefore
assessed AXL expression in the tumours on various treatment
regimes (Fig 8J and K). In untreated tumours, AXL expression was
detectable in distinct areas, while other areas of the tumour were
negative, confirming the idea of AXL heterogeneity in vivo (Fig 8K).
Tumours that had resumed growth on BRAF inhibitor alone
displayed a strong increase in AXL mRNA expression (Fig 8J). In
these “progressed” tumours, nearly all cells stained positive for AXL,
demonstrating that the number of AXL-high cells had increased
(Fig 8K). However, the addition of each of the three EDNR inhibitors
resulted in a profound reduction in AXL expression (Fig 8J and K).
Intriguingly, the reduction in AXL-expressing cells occurred in
patches and resulted in areas of AXL expression and areas of
complete absence of AXL expression, which suggests no general
suppression of AXL expression, but rather a loss of AXL-high cells.
Overall our data lead to a model, whereby in tumours on treat-
ment with BRAF inhibitor-induced MITF up-expression in MITF-
high cells increases intra-tumour EDN1 levels, which can act on
MITF-high (paracrine or autocrine) as well as AXL-high cells to re-
activate ERK (Fig 8L). While in MITF-high cells, BRAF-induced
MAPK signalling is regulating proliferation and survival, partly
through MITF (Wellbrock et al, 2008), in AXL-high cells it only
◀ Figure 8. EDNR signalling is required for proliferation in AXL-high cells.A Nude mice bearing A375 tumours were treated (n = 5–6 mice per group) with vehicle, vemurafenib (25 mg/kg/qd) or BQ788 (10 mg/kg/qd) alone or in combination for
20 days.
B qRT–PCR for DUSP6 from tumours corresponding to the experiment described in (A) and Fig EV6A. P: probability by one-way ANOVA (with Tukey’s post hoc test);
***P < 0.0001 (BRAFi, BRAFi + Macitentan, BRAFi + BQ788), **P = 0.068 (Macitentan) and **P = 0.082 (BQ788). Error bars, min and max values; box limits, second
and third quartiles; horizontal line, median.
C A375 tumour volume on day 18 of treatment with the indicated regimes. P: probability by one-way ANOVA (with Tukey’s post hoc test); ns P > 0.05, ***P = 0.0004
(BQ788), ***P < 0.0001 (Bos + BRAFi, BQ + BRAFi), **P = 0.009 (Mac + BRAFi).
D IHC for Ki67 in A375 xenografts from mice treated as indicated. Scale bar: 50 lm.
E IHC for cleaved caspase-3 in A375 xenografts from mice treated as indicated. Scale bar: 50 lm.
F–J qRT–PCR for EDNRA, EDNRB, MITF, EDN1 and AXL expression in tumours corresponding to the experiment described in (A) and Fig EV6A. P: probability by one-way
ANOVA (with Tukey’s post hoc test); (F) EDNRA: ns P > 0.05, **P = 0.0010 (BQ788), ***P < 0.0001 (BRAFi) and ***P < 0.0001 (BQ788 + BRAFi). (G) EDNRB:
ns P > 0.05, ***P < 0.0001 (BRAFi), ***P = 0.0002 (Mac + BRAFi) and ***P < 0.0001 (BQ788 + BRAFi). (H) MITF: ns P > 0.05, ***P < 0.0001 (BRAFi), ***P = 0.0001
(Mac + BRAFi), and ***P < 0.0001 (BQ788 + BRAFi). (I) EDN1: ns P > 0.05, ***P < 0.0001 (BRAFi), **P = 0.0331 (Mac + BRAFi) and **P = 0.0225 (BQ788 + BRAFi).
(J) AXL: ns P > 0.05, *P = 0.0462 (BQ788) and ***P < 0.0001 (BRAFi).
K IHC for AXL of A375 xenografts from mice treated as indicated. Scale bar: 2,000 lm.
L Model of EDN1-mediated paracrine protection. EDN1 induces re-activation ERK in the presence of BRAF inhibitor. In MITF-high cells, ERK regulates proliferation and
survival, but in AXL-high cells ERK only stimulate proliferation.
Data information: Data are presented as mean  SEM.
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regulates cell cycle progression, whereby other signals are responsi-
ble for survival.
Discussion
Within any tumour, there is a profound amount of innate
variability, which includes genetically and phenotypically differing
cancer cells and stromal cell make-up (De Sousa et al, 2013). This
tumour heterogeneity is not only fuelling cancer progression, but is
also majorly contributing to treatment failure.
Even within MITF-high melanomas MITF displays considerable
heterogeneity in its expression, whereby cells expressing higher and
lower levels of MITF are found within one tumour and located adja-
cent to each other (Chapman et al, 2014; Tirosh et al, 2016). This
heterogeneity is critical for tumour progression as MITF expression
levels define melanoma cell phenotypes of different proliferation
rate and invasiveness, and we have shown recently that a co-opera-
tive communication between these MITF phenotypes can contribute
to an overall increased invasiveness (Chapman et al, 2014). Intrigu-
ingly, MITF heterogeneity can be detected throughout progression
and can even be found in circulating tumour cell clusters (Khoja
et al, 2014), suggesting that maintaining heterogeneity throughout
tumour progression is beneficial for the establishment of advanced
disease.
Another marker for heterogeneity is AXL, which defines a
population of cells with a more de-differentiated and invasive
phenotype (Sensi et al, 2011; Muller et al, 2014). A recent elegant
single-cell analysis revealed that all melanomas contain AXL-high
populations to a certain degree and it is now well accepted that
the AXL-high phenotype is linked to MAPKi therapy resistance
and that there is an enrichment of the AXL-high phenotype in
BRAFi/MEKi therapy post-relapse melanomas (O’Connell et al,
2013; Anastas et al, 2014; Muller et al, 2014; Ji et al, 2015;
Tirosh et al, 2016).
There appears to be no difference in the frequency of AXL-high-
resistant tumours that develop in patients who eventually relapse
on BRAF inhibitor mono or BRAF/MEK inhibitor combination ther-
apy. However, intriguingly, there might be a difference in the initial
response to the different therapies. Exposure of MITF-high cell lines
to MEK inhibitor or a BRAF/MEK inhibitor combination profoundly
enriches for AXL-high cells within less than one week (Tirosh et al,
2016). While this could be due to reduced receptor shedding in
response to MAPK pathway inhibition (Miller et al, 2016), enrich-
ment for AXL-high cells is not a predominant initial reaction when
MITF-high cell lines are treated with BRAF inhibitor alone
(Fig EV1C–F). Tirosh et al reported similar results (Tirosh et al,
2016), suggesting that in the presence of BRAF inhibitor alone an
instant selection for AXL-high subpopulations is outweighed by
other mechanisms that enable individual MITF-high cells to survive
the initial drug insult. We found that paracrine protection via EDNR
signalling can be such a mechanism. Considering that paracrine
protection appears to be not relevant when MEK is inhibited and the
preferred option of BRAF/MEK inhibitor combination therapy in
patients, addition of an EDNR antagonist would not be expected to
create a benefit in this setting. However, our data suggest that a
BRAF/EDNR inhibitor combination could be as potent with the
advantage of not increasing AXL-high expression.
Recently, down-regulation of FRA1 (FOSL1) in response to MAPK
inhibition was identified as common inducer of a paracrine acting
secretome (Obenauf et al, 2015). Importantly, in melanoma FRA1
and MITF expression are mutually exclusive and low FRA1 expres-
sion indicates a cell state with high MITF expression (Muller et al,
2014; Verfaillie et al, 2015). This is entirely in line with our observa-
tion of increased MITF expression in response to MAPK inhibition
and suggests that MITF is contributing to the MAPK inhibitor-
induced secretome downstream of FRA1. Indeed, depletion of FRA1
from melanoma cells leads to up-regulation of MITF (Obenauf et al,
2015), but whether FRA1 directly acts as suppressor ofMITF remains
to be investigated.
Related to the “FRA1-induced” secretome IGF1 was found to
be up-regulated within tumours in response to MAPK inhibition,
and this IGF1 acted on innate-resistant cells supporting their
outgrowth. We did not find IGF1 in our proteomics analysis;
instead, we identified EDN1 as an essential factor within the
MITF-induced secretome. Thereby, MITF not only regulated EDN1
expression, but also the expression of ECE1, the enzyme responsi-
ble for the production of the biologically active EDN1 peptide
(Rossi et al, 2001). While we do not know whether EDN1 is a
direct target gene of MITF, MITF has been identified at the ECE1
promoter in ChIP-seq experiments (Strub et al, 2011). The EDN
signalling pathway is closely linked to MITF and is crucial for the
melanocytic lineage during development, but also in adult mela-
nocytes (Saldana-Caboverde & Kos, 2010). This epistatic link is
reflected in individual forms of Waardenburg syndrome (WS), an
inherited sensorineural deafness condition, in which MITF muta-
tions are implicated in WS type IIA and mutations in EDNRB (the
relevant EDN receptor in melanocytic cells) in WS type IV (Sal-
dana-Caboverde & Kos, 2010). Intriguingly, in the mouse Ednra is
expressed in migrating neural crest cells (Clouthier et al, 1998),
which are the de-differentiated precursors of melanocytes. This
observation is entirely in line with the AXL-high phenotype of de-
differentiation and increased motility and invasion (Sensi et al,
2011; O’Connell et al, 2013; Anastas et al, 2014; Konieczkowski
et al, 2014; Muller et al, 2014; Ji et al, 2015; Tirosh et al, 2016).
Thus, the neural crest origin, but de-differentiated nature of AXL-
high melanoma cells might explain why they express preferen-
tially EDNRA, while differentiation towards the melanocyte
lineage, triggered by MITF expression, results in a switch to
EDNRB expression. A similar distribution of receptors amongst
phenotypes corresponding to MITF-high and AXL-high has been
found with the WNT5A receptors ROR1 and ROR2, respectively
(O’Connell et al, 2013). However, instead of maintaining both
phenotypes, the presence of WNT5A results in down-regulation of
ROR1 and induction of a phenotype switch (O’Connell et al,
2013). Thus, WNT5A rather contributes to the establishment of
the AXL-high phenotype than the maintenance of heterogeneity.
Indeed, it appears crucial for the maintenance of heterogeneity
that both phenotypes still respond to and are supported by EDN1.
We show that while EDNR signalling protects MITF-high cells, it is
also required for the AXL-high phenotype during treatment. This
suggests that as long as the MAPK pathway is inhibited the
increased EDN1 expression “nurtures” the otherwise under-repre-
sented population of AXL-high cells, which eventually can re-estab-
lish tumour growth in the presence of inhibitor even when pathway
re-activation occurs and EDN1 levels drop again.
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Our findings of EDN1 as unique regulator of phenotype hetero-
geneity maintenance and paracrine protection from BRAF inhibition
add a novel feature to EDN1, which is known to be involved in many
aspects of cancer development including EMT and chemotherapy
resistance (Rosano et al, 2013). Interestingly, both EDNRB- and
EDNRA-specific inhibitors had the potential to improve the response
to BRAF inhibition, which appeared to be due to additional effects
on the microenvironment, particularly endothelial cells and fibrob-
lasts. EDN1 is well known to support tumour growth and progres-
sion through acting on the microenvironment (Rosano et al, 2013),
and hence, interfering with EDNR signalling apart from targeting
melanoma cell phenotypes could have the additional benefit of
suppressing a favourable tumour microenvironment. Moreover,
because the EDN1-induced paracrine signalling has the potential to
support both MITF-high and AXL-high phenotypes in acquired resis-
tant tumours, targeting the EDN1-EDN receptor axis could reduce
the complexity seen in patients treated with MAPK inhibitor at time
of progression.
Materials and Methods
Cell culture treatments and drug dose–response analysis
Melanoma cell lines were grown in DMEM/10% FCS. Cell numbers
were measured as the optical density at 595 nm (OD595) of solubi-
lized crystal violet from formalin fixed cells. For all in vitro experi-
ments, vemurafenib was used as BRAF inhibitor. Different MEK
inhibitors (PD184352, selumetinib and trametinib) were used and
are specified in the figure legends. For dose–response curves, cells
were plated in 96-well plates and treated with serial dilutions of the
indicated drugs. The GI50 was calculated using GraphPad Prism
version 6.00 (San Diego California, USA).
Patient samples
Patients with mutant BRAFV600-positive metastatic melanoma were
treated with either a BRAF inhibitor, or a combination of BRAF and
MEK inhibitors (for patient characteristics, see Appendix Table S1).
All patients were consented for tissue acquisition per an IRB-
approved protocol (Office for Human Research Studies, Dana-
Farber/Harvard Cancer Center). Tumour biopsies were obtained
before treatment or at the indicated days of treatment.
In vivo xenograft studies
All animal procedures involving animals were ethically approved
by University of Manchester Animal Welfare and Ethical Review
Bodies (AWERB) and carried out under licence in accordance with
the UK Home Office Animals (Scientific Procedures) Act (1986),
the guidelines of the Committee of the National Cancer Research
Institute (Workman et al, 2010) and the University’s Policy on the
Use of Animals in Research. Animals were housed in the Univer-
sity of Manchester Biological Safety Unit. CD1 nude mice (fe-
male, 8 weeks of age) were injected s.c. with 4 × 106 A375 cells
(in PBS). When animals had developed melanoma nodules of
~100 mm3, drug administration was initiated (n = 5–6 mice per
group). Treatment was by oral gavage once daily with vehicle
(5% DMSO, 95% water), or the respective drugs as indicated.
After the indicated number of days, tumours were isolated and
analysed as described. Zebrafish (Danio rerio) were raised and
maintained at the University of Manchester Biological Services
Unit. Zebrafish xenografts were generated by injection of approxi-
mately 1,000 melanoma cells in total (for details see
Appendix Table S3) into the space surrounding the heart of
embryos 48 h post-fertilization. Subsequently, groups of six larvae
per condition randomly assigned were treated with either vemu-
rafenib (200 nM) or the vehicle DMSO. The drug was added to the
fish medium, and larvae were grown at 34°C ambient temperature
in chorion water. Before drug addition (day 1) and 3 days after
drug addition, anesthetized larvae were imaged using a Leica SP5
confocal microscope. Images were processed using Volocity soft-
ware (Perkin Elmer, Cambridge, UK).
Time-lapse FUCCI cell cycle analysis
To generate WM164 melanoma cell lines stably expressing the
FUCCI constructs, mKO2-hCdt1 (30–120) and mAG-hGem (1–110)
(Sakaue-Sawano et al, 2008) were subcloned into a replication-
defective, self-inactivating lentiviral expression vector system and
the lentivirus was produced by co-transfection of human embryonic
kidney 293T cells. High-titre viral solutions for mKO2-hCdt1
(30/120) and mAG-hGem (1/110) were prepared and used for
co-transduction into melanoma cell lines and subclones were gener-
ated by single-cell sorting (Haass et al, 2014). Cells were seeded in
multiwell tissue culture plates, and time-lapse microscopy was
performed using an Olympus IX-81 inverted fluorescence micro-
scope equipped with an incubation chamber at 37°C and 5% CO2.
Images were taken at intervals of 15 min using 10× objective. Cells
were treated with 160 nM dabrafenib, 80 nM trametinib or equiva-
lent DMSO volumes. DRAQ7 dye (Beckman Coulter) was added to
all conditions to a final concentration of 3 lM to track cell death.
Cells were monitored and the occurrence of cell cycle phases as well
as cell death recorded.
Melanoma 3D spheroid growth
Melanoma cells were re-suspended in Dulbecco’s modified Eagle’s
medium containing 5% foetal bovine serum and 0.32% methylcellu-
lose (Sigma). The cell suspension was transferred into a 96-well
plate (1,000 cells per well), and spheres were allowed to form over
a period of 48–72 h as previously described (Ferguson et al, 2013).
Spheres were then transferred into 0.5-ml fibrillar bovine dermal
collagen (2.3 mg/ml; Nucaton, Leimuiden, The Netherlands) with
one sphere per well of a 24-well plate. Once the collagen was set,
Dulbecco’s modified Eagle’s medium containing 10% foetal bovine
serum was added, and after approximately 16 h, drugs were added
to the medium at indicated concentrations.
Statistical analysis
If not indicated otherwise, data represent the results for assays
performed in triplicate, with error bars to represent standard devia-
tions or errors from the mean. Statistics used were as follows: predom-
inately Student’s t-test and one-way ANOVA with Tukey’s post hoc
test performed using GraphPad Prism version 6.0a for Mac OS,
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GraphPad Software, San Diego, California, USA, www.graphpad.com.
Pearson correlation was used to analyse associated gene expression.
Expanded View for this article is available online.
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